Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of...

Area of Science:

• Nephrology
• Infectious Diseases
• Clinical Pharmacy

Background:

• Peritoneal dialysis (PD) patients are at risk for exit-site infections (ESIs) and peritonitis, often caused by Staphylococcus aureus (SA).
• Catheter exit-site care is crucial in preventing PD-related infections.
• SA infections are associated with significant morbidity and mortality in PD patients.

Purpose of the Study:

• To assess the efficacy of mupirocin ointment in preventing SA exit-site infections (ESIs) and peritonitis in PD patients.
• To evaluate the impact of mupirocin application on overall peritonitis rates in PD patients.

Main Methods:

• Prospective, historically controlled study involving 181 PD patients applying mupirocin at the exit site (Study 1).
• Comparison of a mupirocin-treated group (70 patients) with a historical control group (118 patients) for CAPD patients (Study 2).
• Mupirocin was applied daily or three times weekly; patients were not screened for SA carriage.

Main Results:

• Mupirocin application significantly reduced SA ESIs (0.11 to 0.01 episodes/patient/year) and SA peritonitis (0.19 to 0.06 episodes/patient/year) in Study 1.
• Study 2 showed significantly lower SA ESI incidence (0.14 vs. 0.06 episodes/patient/year) and SA peritonitis (0.16 vs. 0.06 episodes/patient/year) in the mupirocin group.
• Overall peritonitis rates decreased significantly in Study 1 (0.87 to 0.48 episodes/patient/year); no significant adverse effects were noted.

Conclusions:

• Topical mupirocin application at the exit site is effective in reducing SA-related infections in PD patients.
• This prophylactic measure can decrease the incidence of SA exit-site infections and peritonitis.
• Mupirocin treatment may contribute to improved long-term survival for patients on CAPD by mitigating infection-related complications.